Nu Skin Aging Research Presented at International Longevity and Aging Conference
PROVO, Utah, July 13 /PRNewswire-FirstCall/ — Nu Skin Enterprises, Inc. (NYSE: NUS) and its research partner LifeGen Technologies presented their latest research findings on how dietary interventions affect aging and longevity at the First International Congress on Controversies in Longevity, Health and Aging (CoLONGY) in Barcelona, Spain. Nu Skin and its exclusive partner, LifeGen Technologies, presented research on the identification of genetic biomarkers of aging, and how gene expression can be modulated by dietary interventions.
“Nu Skin’s ageLOC approach to anti-aging looks at the level of genetic expression of aging and is supported by our partnerships with some of the best minds in anti-aging science, such as our colleagues at LifeGen Technologies,” said Joseph Chang, Ph.D., Nu Skin chief scientific officer and executive vice president of product development. “Identifying functional Youth Gene Clusters and understanding how ingredients can target and reset those genes to a more youthful profile helps us develop next-generation skin care and nutritional products.”
Jamie Barger, Ph.D., director of laboratory operations for LifeGen, presented the joint research that has identified robust, tissue-specific panels of transcriptional biomarkers that are relevant to aging. Studies using whole-genome profiles of gene expression have identified thousands of genes that change activity patterns with age. Nu Skin is currently using these biomarkers in a pre-clinical study of dietary compounds to determine their ability to impact aging at the genetic expression level.
This fall Nu Skin will introduce a new dietary supplement to address a key concern of aging — loss of vitality. ageLOC Vitality builds on the research presented at the CoLONGY conference and the company has submitted a patent application for the unique blend of ingredients that have been identified with this technology to support youthful genetic expression of vitality.
CoLONGY is an exclusive forum for international experts in health, science and aging to share and compare recent findings and research. Scientists, doctors and researchers come together to discuss and understand the processes of aging in relation to health.
About LifeGen Technologies
Nu Skin collaborates with LifeGen in an exclusive agreement by leveraging LifeGen’s proprietary methods regarding gene expression profiling and pathways affected by aging. The mission of LifeGen Technologies is to discover the genetic basis of the aging process with the ultimate goal of increasing a healthy life span. LifeGen’s pioneering research has resulted in several pending patents, and ongoing research undertaken in collaboration with Nu Skin is expected to yield further important intellectual property. LifeGen’s patent for the use of “gene expression profiling” as a method to measure the progression of the aging process at the molecular level in individual organs is a key component of the partnership.
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. Nu Skin’s scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company, evidenced in its unique ageLOC(TM) science that addresses aging at its source. The company’s anti-aging products feature the new ageLOC family of skin care products including ageLOC Future Serum and the ageLOC Edition Galvanic SpaÂ® System II, as well as Tru FaceÂ® Essence Ultra and LifePakÂ® Nano. A global direct selling company, Nu Skin operates in 50 markets worldwide and has more than 765,000 independent sales representatives. Nu Skin is traded on the New York Stock Exchange under the symbol “NUS.” More information is available at http://www.nuskin.com.
Please note: This press release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the company’s results of operation and strategy. These forward-looking statements are based on current information and expectations, and are subject to risks and uncertainties discussed in company filings with the U.S. Securities and Exchange Commission, which could cause the company’s actual results to differ materially from expected results. The company undertakes no obligation to publicly update any forward-looking statement contained in this press release, whether as a result of new information, future developments or otherwise, except as may be required by law.
SOURCE Nu Skin Enterprises, Inc.